Immunohistochemical detection of p53 protein expression in various childhood astrocytoma subtypes: Significance in tumor progression

Anticancer Research

Volumn 17, Issue 2 A, 1997, Pages 1187-1194

  Bodey, Bela ^a,e   Gröger, Angela M ^b   Bodey Jr , Bela ^a   Siegel, Stuart E ^c   Kaiser, Hans E ^b,d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF VIENNA   (Austria)

^c CHILDREN S HOSPITAL LOS ANGELES   (United States)

^d UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^e NONE   (United States)

Author keywords

Antigen epitope retrieval; Astrocytoma subtypes; Carcinogenesis; DNA repair; Genetic instability; Heat shock protein; Immunocytochemistry; Malignant cell immunophenotype; Mouse anti human p53 monoclonal antibody; Mutant p53; p21; Peroxidase conjugation; Point mutation; Streptavidin biotin conjugation; Wild type p53

Indexed keywords

BIOTIN; PEROXIDASE; PROTEIN P53; STREPTAVIDIN;

ARTICLE; ASTROCYTOMA; CELL CLONE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; GENE MUTATION; GLIOBLASTOMA; HUMAN; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; IMMUNOREACTIVITY; NEUROECTODERM TUMOR; OLIGODENDROGLIOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR GROWTH;

ANIMALS; ASTROCYTOMA; CHILD; HUMANS; IMMUNOHISTOCHEMISTRY; MICE; MUTATION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 1842299258     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (86)

1. Virchow R: Cellular patholgy, p 277, John Churchill, London, 1860.
2. Williams BP, Abney ER, RaffMC: Macroglial cell development in embryonic rat brain: studies using monoclonal antibodies, flourescence-activated cell sorting and cell culture. Dev Biol 112:126-134, 1985.
3. Katsura S, Suzuki J, Wada T: Statistical study of brain tumours in the neurosurgical clinics in Japan. J Neurosurg 16: 570-580, 1959.
4. von Deimling A, Louis DN, Wiestier OD: Molecular pathways in the formation of gliomas. Glia 75: 328-338, 1995.
5. Kleihues P, Soylemezoglu F, Schauble B, Scheithauer BW, Burger PC: Histopathology, classification, and grading of gliomas. Glia 75: 211-221, 1995.
6. Cairncross JG: The biology of astrocytoma: lessons learned from chronic myelogenous leukemia-hypothesis. J Neuro-Oncol 5: 99-104, 1987.
7. Greaves M, Janossy G, Francis G, Minowada J: Membrane phenotypes of human leukemic cells and leukemic cell lines: Clinical correlates and biological implications. In: B Clarkson, PL Marks, and J Till (eds). Differentiation of normal and neoplastic hemopoictic cells, Vol 5, pp 823-841, Cold Spring Harbor Conferences on Cell Proliferation, Cold Spring Harbor Laboratory, New York, 1977.
8. Bums BF: Molecular genetic markers in lymphoproliferative disorders. Clin Biochem 22: 33-39, 1989.
9. Bodey B, Zeltzer PM, Saldivar V, Kemshead J: Immunophenotyping of childhood astrocytomas with a library of monoclonal antibodies. Int J Cancer 45: 1079-1087, 1990.
10. Bullard DE, Gillespie Y, Mahaley MS, Bigner DD: Immunobiology of human gliomas. Semin Oncol 13: 94-109, 1986.
11. Ohgaki K, Schauble B, zur Hausen A, von Ammon K, Kleihues P: Genetic alterations associated with the evolution and progression of astrocytic brain tumors. Virchows Arch 427: 113-118, 1995.
12. Lane DP, Crawford LV: T-antigen is bound to host protein in SV40-transformed cells. Nature 278: 261-263, 1979.
13. Sarnow P, Ho YS, Williams J, Levine AJ: Adenovirus Elb-58kd tumor antigen and SV40 large tumor antigen are physically associated with the same 54 kd cellular protein in transformed cells. Cell 28: 387-394, 1982.
14. Werness BA, Levine AJ, Howley PM: Association of human papillomavirus types 16 and 18 E6 proteins with p53. Science 248: 76-79, 1990.
15. Marshall CJ: Tumor suppressor genes. Cell 64: 313-326, 1991.
16. Bartek J, Bartkova J, Vojtesek B, Staskova Z, Lukas J, Rejthar A, Kovarik J, Midgley CA, Gannon JV, Lane DP: Aberrant expression of the p53 oncoprotein is a common feature of a wide spectrum of human malignancies. Oncogene 6: 1699-1703, 1991.
17. Carbon de Fromentel C, Soussi T: TP53 tumor suppressor gene: a model for investigating human mutagenesis. Genes Chromosomes Cancer 4: 1-15, 1992.
18. Greenblatt MS, Bennett WP, Hollstein M, Harris CC: Mutations in the p53 tumor suppressor genes: clues to cancer etiology and molecular pathogenesis. Cancer Res 54: 4855-4878, 1994.
19. Chen P, lavarone A, Fick J, Edwards M, Prados M, Israel MA: Constitutional p53 mutations associated with brain tumors in young adults. Genet Cytogenet 82: 106-115, 1995.
20. Kyritsis AP, Xu R, Bondy ML, Levin VA, Bruner JM: Correlation of p53 immunoreactivity and sequencing in patients with glioma. Molec Carcinogen 75: 1-4, 1996.
21. Cho MY, Jung SH, Kim TS: p53 protein overexpression in astrocytic neoplasms. Yonsei Med J 36: 521-526, 1995.
22. Ellison DW, Steart PV, Bateman AC, Pickering RM, Palmer JD, Weller RO: Prognostic indicators in a range of astrocytic tumours: an immunohistochemical study with Ki-67 and p53 antibodies. J Neurol Neurosurg Psych 59: 413-419, 1995.
23. Kordek R, Biernat W, Alwasiak J, Maculewicz R, Yanagihara R, Liberski PP: p53 protein and epidermal growth factor receptor expression in human astrocytomas. J Neuro-Oncol 26: 11-16, 1995.
24. Lane DP: p53, guardian of the genome. Nature 358: 15-16, 1992.
25. Kern S, Kinzler KW, Bruskin A, Jarosz D, Friedman P, Prives C, Vogelstein B: Identification of p53 as a sequence-specific DNA-binding protein. Science 252: 1708-1711, 1991.
26. Bargonetti J, Friedman PN, Kern SE, Vogelstein B, Prives C: Wild-type but not mutant p53 immunopurified proteins bind to sequences adjacent to the SV40 origin of replication. Cell 65: 1083-1091, 1991.
27. Marx J: New link found between p53 and DNA repair. Science 206: 1321-1322, 1994.
28. Bischoff JR, Friedman PN, Marshak DR, Prives C, Beach D: Human p53 is phosphorylated by p60-cdc2 and cyclin B-cdc2. Proc Natl Acad Sci USA 87: 4766-4770, 1990.
29. Meek DW, Simon S, Kikkawa U, Eckhart W: The p53 tumor suppressor protein is phosphorylated at serine 389 by casein kinase II. EMBO J 9: 3253-3260, 1990.
30. Wang EH, Friedman PN, Prives C: The murine p53 protein blocks replication of SV40 in vitro by inhibiting the initiation functions of SV40 large T antigen. Cell 57: 379-392, 1989.
31. Raycroft L, Wu H, Lozano G: Transcriptional activation by wild-type but not transforming mutants of the p53 anti-oncugene. Science 249: 1049-1051, 1990.
32. Zhang W, Funk WD, Wright WE, Shay JW, Deisseroth AB: Novel DNA binding of p53 mutants and their role in transcriptional activation. Oncogene 8: 2555-2559, 1993.
33. Bogler O, Huang El, Kleihues P, Cavenee WK: The p53 gene and its role in human brain tumors. Glia 15: 308-327, 1995.
34. Sun Y, Nakamura K, Wendel E, Colburn NH: Progression toward tumor cell phenotype is enhanced by overexpression of a mutant p53 tumor suppressor gene isolated from nasopharyngeal carcinoma. Proc Natl Acad Sci USA 90: 2827-2831, 1993.
35. Eeles RA, Warren W, Knee G, Bartek J, Averill D, Stratton MR, Blake PR, Tait DM, Lane DP, Easton DF: Constitutional mutation in exon 8 of the p53 gene in a patient with multiple primary tumours: molecular and immunohistochemical findings. Oncogene 8: 1269-1276, 1993.
36. Goldblum JR, Bartos RE, Carr KA, Frank TS: Hepatitis B and alterations of the p53 tumor suppressor gene in hepatocellulur carcinoma. Am J Surg Pathol 17: 1244-1251, 1993.
37. Renault B, van den Broek M, Fodde R, Wijnen J, Pellegata NS, Arhadori D, Khan PM, Ranzani GN: Base transitions are the most frequent genetic changes at p53 in gastric cancer. Cancer Res 53: 2614-2617, 1993.
38. Iggo R, Gatter K, Bartek J, Lane D, Harris AL: Increased expression of mutant forms of p53 oncogene in primary lung cancer. Lancet 335: 675-679, 1990.
39. Sturzbecher HW, Chumakov P, Welch WJ, Jenkins JR: Mutant p53 proteins bind hsp 72.73 cellular heat shock-related proteins in SV40-transformed monkey cells. Oncogene 1: 201-211, 1987.
40. Finlay CA, Hinds PW, Tan T-H, Eliyahu D, Oren M, Levine AJ: Activating mutations for transformation by p53 produce a gene product that forms an hsc70-p53 complex with an altered half-life. Mol Cell Biol 8: 531-539, 1988.
41. Banks L, Matlashewski G, Crawford L: Isolation of human p53 specific monoclonal antibodies and their use in the studies of human p53 expression. Eur J Biochem 159: 529-534, 1986.
42. Bartek J, Bartkova J, Lukas J, Staskova Z, Vojtesek B, Lane DP: Immunohistochemical analysis of the p53 oncoprotein on paraffin sections using a series of novel monoclonal antibodies. J Pathol 169: 27-34, 1993.
43. Home GM, Anderson JJ, Tiniakos DG, McIntosh GG, Thomas MD, Angus B, Henry JA, Lennard TW, Horne CH: p53 protein as a prognostic indicator in breast carcinoma: a comparison of four antibodies for immunohistochemistry. Brit J Cancer 73: 29-35, 1996.
44. Hsu SM, Raine L, Fanger H: Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison of ABC and unlabeled antibody (PAP) procedure. J Histochem Cytochem 29: 577-581, 1981.
45. Shi S-R, Key ME, Kalra KL: Antigen retrieval in formalin fixed, paraffin-embedded tissues: an enhancement method for immuno-histochemical staining based on microwave oven heating of tissue sections. J Histochem Cytochem 39: 741-748, 1991.
46. Shi S-R, Cote C, Kalra KL, Taylor CR, Tandon AK: A technique for retrieving antigens in formalin-fixed, routinely acid-decalcified, celloidin-embedded human temporal bone sections for immunohistochemistry. J Histochem Cytochem 40: 787-792, 1992.
47. Bodey B, Kaiser HE, Goldfarb RH: Immunophenotypically varied cell subpopulations in primary and metastatic human melanomas. Monoclonal antibodies for diagnosis, detection of neoplastic progression and receptor directed immunotherapy. Anticancer Res 16: 517-531, 1996.
48. Bodey B, Groger AM, Bodey B Jr, Luck JV, Kaiser HE: Immunocytochemical detection of p53 protein overexpression in primary human osteosarcomas. Anticancer Research, 1996. In press.
49. Hollstein M, Sidransky D, Vogelstein B, Harris C: p53 mutations in human cancers. Science 253: 252-254, 1991.
50. Malkin D, Li FP, Strong LC, Fraumeni JF Jr, Nelson CE, Kim DH, Kassel J, Gryka MA, Bischoff FZ, Tainsky MA: Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 250: 1233-1238, 1990.
51. Srivastava S, Zou ZQ, Pirollo K Blattner W, Chang EH: Germ-line transmission of a mutated p53 gene in cancer-prone family with Li- Fraumeni syndrome. Nature 348: 747-749, 1990.
52. Gaidano G, Ballerini P, Gong JZ, Inghirami G, Neri A, Newcomb EW, Magrath IT, Knowles DM, Dalla-Favera R: p53 mutations in human lymphoid malignancies: Association with Burkitt lymphoma and chronic lymphocytic leukemia. Proc Natl Acad Sci USA 88: 5413-5417, 1991.
53. Lee CS, Pirdas A, Lee MW: p53 in cutaneous melanoma: immunoreactivity and correlation with prognosis. Australasian J Dermatol 36: 192-195, 1995.
54. Bergman R, Shemer A, Levy R, Friedman-Bimbaum R, Trau H, Lichtig C: Immunohistochemical study of p53 protein expression in Spitz nevus as compared with other melanocytic lesions. Amer J Dermatopathol 17: 547-550, 1995.
55. Sparrow LE, English DR, Heenan PJ, Dawkins HJ, Taran J: Prognostic significance of p53 over-expression in thin melanomas, Melanoma Res 5: 387-392, 1995.
56. Weiss J, Heine M, Arden KC, Komer B, Pilch H, Herbst RA, Jung EG: Mutation and expression of TP53 in malignant melanomas. Recent Results Cancer Res 139: 137-154, 1995.
57. Takahashi T, Nau MM, Chiba T, Birrer MJ, Rosenberg RK, Vinocour M, Levitt M, Pass H, Gazdar AF, Minna JD: p53: a frequent target for genetic abnormalities in lung cancer. Science 246: 491-494, 1989.
58. Miller CW, Simon K, Aslo A, Kok Y, Yokota J, Buys CHCM, Terada M, Koeffler HP: p53 mutations in human lung tumors. Cancer Res 52: 1695-1698, 1992.
59. Husgafvel-Pursiainen K, Ridanpaa M, Anttila S, Vainio H: p53 and ras gene mutations in lung cancer: implications for smoking and occupational exposures. J Occupat Environ Med 37: 68-76, 1995.
60. Kawajiri K. Eguchi H, Nakachi K, Sekiya T, Yamamoto M: Association of CYP1A1 germ line polymorphisms with mutations of the p53 gene in lung cancer. Cancer Res 56: 72-76, 1996.
61. Boers JE, ten Velde GP, Thunnissen FB: p53 in squamous metaplasia: a marker for risk of respiratory tract carcinoma. Amer J Resp Crit Care Medicine 153: 411-416, 1996.
62. Kondo K, Tsuzuki H, Sasa M, Sumimoto M, Uyama T, Monden Y: The dose-response relationship between the frequency of p53 mutations and tobacco consumption in lung cancer patients. J Surg Oncol 61: 20-26, 1996.
63. Tsai CM, Chang KT, Wu LH, Chen JY, Gazdar AF, Mitsudomi T, Chen MH, Pemg RP: Correlations between intrinsic chemoresistance and HER-2/neu gene expression, p53 gene mutations, and cell proliferation characteristics in non-small cell lung cancer cell lines. Cancer Res 56: 206-209, 1996.
64. Ozturk M: p53 mutation in hepatocellular carcinoma after aflatoxin exposure. Lancet 338: 1356-1359, 1991.
65. Hsu HC, Tseng HJ, Lai PL, Lee PH, Peng SY: Expression of p53 gene in 184 unifocal hepatocellular carcinomas: association with tumor growth and invasiveness. Cancer Res 55: 4691-4694, 1993.
66. Tabor E: Tumor suppressor genes, growth factor genes, and oncogcnes in hepatitis B virus-associated hepatocellular carcinoma. J Med ViroI 42: 357-365, 1994.
67. Campbell IG, Eccles DM, Dunn B, Davis M, Leake V: p53 polymorphism in ovarian and breast cancer. Lancet 347: 393-394, 1996.
68. Callahan R: p53 mutations, another breast cancer prognostic factor. J Natl Cancer Inst 84: 826-827, 1992.
69. Harris AL: p53 expression in human breast cancer. Adv Cancer Res 59:69-88, 1992.
70. Eeles RA, Bartkova J, Lane DP, Bartek J: The role of TP53 in breast cancer development. Cancer Surv 18: 57-75, 1993.
71. Elledgc RM, Allred DC: The p53 tumor suppressor gene in breast cancer. Breast Cancer Res Treat 32: 39-47, 1994.
72. Karameris AM, Worthy E, Gorgoulis VG, Ouezado M, Anastassiades OT: p53 gene alterations in special types of breast carcinoma: a molecular and immunohistochemical study in archival material. J Pathol 776: 361-372, 1995.
73. Ozbun MA, Butel JS: Tumor suppressor p53 mutations and breast cancer: a critical analysis. Adv Cancer Res 66: 71-141, 1995.
74. Kovach JS, Hartmann A, Blaszyk H, Cunninghum J, Schaid D, Sommer SS: Mutation detection by highly sensitive methods indicates that p53 gene mutations in breast cancer can have important prognostic value. Proc Natl Acad Sci USA 93: 1093-1096, 1996.
75. Nigro JM, Baker SJ, Preisinger AC, Jessup JM, Hostetter R, Cleary K, Bigner SH. Davidson N, Baylin S, Devilee P, Glover T, Collins FS, Weston A, Modali R, Harris CC, Vogelstein B: Mutations in the p53 gene occur in diverse human tumour types. Nature 342: 705-708, 1989.
76. Bruner JM, Saya H, Moser PR: Immunocytochemical detection of p53 in human gliomas. Med Pathol 4: 671-674, 1991.
77. Kuramitopoulou E, Perente E, Diamantis I: p53 protein expression in central nervous system tumours: an immunohistochemical study with CM1 polyvalent and DO-7 monoclonal antibodies. Acta Neuropathol 85: 611-616, 1993.
78. Ellison D, Gatter K, Steart P, Lane D, Weller RO: Expression of the p53 protein in a spectrum of astrocytic tumors, J Pathol 168: 383-386, 1992.
79. von Deimling A. Bender B, Jahnke R, Waha A, Kraus J, Alhrecht S, Welenreuther R, Faßbender F, Nagel J, Menon AG, Louis DN, Lenartz DD, Schramm J, Wiestier OD: Loci associated with malignant progression in astrocytomas: A candidate on chromosome 19q. Cancer Res 54: 1397-1401, 1994.
80. Fults D, Petronio J, Noblett BD, Redone CA: Chromosome 11p15 deletions in human malignant astrocytomas and primitive neuroectodermal tumors. Genomics 14: 799-801, 1992.
81. James CD, Carlblom E, Dumanski JP, Hansen M, Nordenskjold M, Collins VP, Cavenee WK: Clonul genomic alterations in glioma malignancy stages. Cancer Res 48: 5546-5551, 1988.
82. James CD, He J, Carlblom E, Nordenskjold M, Cavenee WK, Collins VP: Chromosome 9 deletion mapping reveals interferon alpha and interferon beta-1 gene deletions in human glial tumors. Cancer Res 57: 1684-1688, 1991.
83. Olopade OI, Buchhagen DL, Malik K, Sherman J, Nobori T, Bader S, Nau MM, Gazdar AF, Minna JD, Diaz MO: Homozygous loss of the interferon genes defines the critical region on 9p that is deleted in lung cancers. Cancer Res 53: 2410-2415, 1993.
84. Ransom DT, Ritland SR, Kimmel DW, Moertel CA, Dahl RJ, Scheithauer BW, Kelly PJ, Jenkins BR: Cytogenetic and loss of heterozygosity studies in ependymoma. pilocytic astrocytoma and oligodendrogliomas. Genes Chromosom Cancer 5: 348-356, 1992.
85. Venter DJ, Bevan KL, Ludwig RL, Riley TEW, Jat PS, Thomas DGT, Noble MD: Retinoblastoma gene deletions in human glioblastomas. Oncogene 6: 445-448, 1991.
86. von Deimling A, Eibl RH, Ohgaki H, Louis DN, von Ammon K, Petersen I, Kleihues P, Chung RY, Wiestler OD, Seizinger BR: p53 mutations are associated with 17p allelic loss in grade II and grade III astrocytoma. Cancer Res 52: 2987-2990, 1992.